TNF-α and TNF-R-1 level in pregnancy with ecotopic pregnancy
Keywordsectopic pregnancy, methotrexate, tumor necrotic factor and tumor necrotic factor receptor 1
The aim of our work was to study the relationship of tumor necrotic factor and receptor 1 to tumor necrotic factor in physiological uterine pregnancy in the first trimester and in pregnant women with ectopic pregnancy who received different doses of cytostatic methotrexate for its treatment.
Methods and materials
We analyzed the results of special research methods and examined 30 pregnant women with advanced uterine pregnancy in the first trimester and 40 pregnant women with advanced ectopic pregnancy treated with methotrexate, depending on the dose of methotrexate patients were divided into 2 groups of 20 women. The first group (M1) received 75-100 mg (based on kg of weight) of methotrexate intramuscularly, and the second group (M2) received methotrexate at a dose of 75-100 mg twice after 7 days.
In healthy pregnant women with physiological pregnancy for 3-4 weeks, the level of TNF-α in blood neutrophils was within 2.02 ± 0.16 ng / ml and in pregnant women with ectopic pregnancy - 2.64 ± 0.19 ng / ml. In the M1 group, TNF-α level was slightly higher (5.49 ± 0.24 ng / ml, p <0.01) than in the group of women with ectopic pregnancy before treatment (2.64 ± 0.19) ng / ml, whereas in the methotrexate (M2) reintroduction group this indicator increased almost 4 times (10.30 ± 0.26 ng / ml) and in the M1 group almost 2.3 times (5.49 ± 0.24) ng / ml). The number of activated TNF-R1 neutrophils in the M1 group was (11.16 ± 0.30) ng / ml, versus (16.26 ± 0.43) ng / ml in the M2 group (p <0.05).
Neutrophil blood cells are sensitive cells of the body to study the assessment of the depth of action of cytostatic at the body level as a whole.
Indicators of tumor necrotic factor and receptor 1 tumor necrotic factor can be used as a marker of activity of cytotoxic action of different doses of methotrexate for the treatment of progressing ectopic pregnancy.
Guriev, T.D.; Sidorova, I.S. Ectopic pregnancy. Practical gynecology: Moscow, Russia,2007; p. 96.ISBN: 5-98811-060-6.
Boychuk, A.; Yakymchuk, Y. Results of operative andconservative metods oftreatment ectopic pregnancies. Actual Problems of Pediatry, Obstetrics and Gynecology 2016, 2. doi:10.11603/24116-4944.2016.2.6857.
Boychuk, A.; Kurylo, O.U.; Tolokova, T. Prevention of Adhesions in The Preservation of Reproductive Health of Women with Endometryoid Cysts.Rec. J. Pharm., Biol. Chem. Sci.2017, 8(3), 1447–1454. ISSN: 0975-8585
Boychuk, A.V.; Yakymchuk, Yu.B.; Yakymchuk, O.M.Violation of homocysteine exchange in conservative treatment of ectopic pregnancy. Collection of scientific papers of the Association of Obstetricians-gynecologists of Ukraine. Polygraph plus: Kyiv, 2014;p. 354. ISBN 978-966-8977-45-9.
Сohen, A.; Zakar, L.; Gil, Y.; Amer-Alshiek, J.; Bibi, G.; Almog, B.; Levin, I.Methotrexate success rates in progressing ectopic pregnancies: a reappraisal. Am J Obstet Gynecol., 2014, 211(2), 128.e1-5. doi:10.1016/j.ajog.2014.03.043
Tong, S.; Skubisz, M.M.; Horne, A.W. Molecular diagnostics and therapeutics for ectopic pregnancy. Mol. Hum. Reprod.2015, 21(2), 126–135. doi:10.1093/molehr/gau084.
Brady, P.C. New Evidence to Guide Ectopic Pregnancy Diagnosis and Management.Obstet Gynecol Surv.2017, 72(10), 618–625. doi:10.1097/OGX.0000000000000492.
Talwar,P.; Sandeep, K.; Naredi. N.; Duggal,B.S.; Jose,T.Systemic methotrexate: An effective alternative to surgery for management of unruptured ectopic pregnancy. Med J Armed Forces India. 2013, 69(2), 130–133.doi:10.1016/j.mjafi.2012.08.032.
Latchesar Tantchev 1,* , Andrey Kotzev 2 and Angel Yordanov 3Disturbed Interstitial Pregnancy: A First Case of Successful Treatment Using a Mini-Laparoscopic Approach Medicina 2019, 55, 215; doi:10.3390/medicina55050215
How to Cite
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Number of views and downloads: 230
Number of citations: 0